THOXF (Bioporto AS) Other Current Receivables: $0.18 Mil (As of Dec. 2025)


THOXF Bioporto AS THOXF
69 GF Score
Price $0.15
GF Value $0.16
! 3 Warning Signs
View Full Analysis

What is Bioporto AS Other Current Receivables?

Bioporto AS THOXF 69 Other Current Receivables is $0.18 Mil as of Dec. 2025. GuruFocus rates THOXF with a GF Score™ of 69/100 and a GF Value™ of $0.16. The stock has 3 warning signs investors should review.

Bioporto AS's Other Current Receivables for the quarter that ended in Dec. 2025 was $0.18 Mil.

Bioporto AS's quarterly Other Current Receivables declined from Jun. 2025 ($0.29 Mil) to Sep. 2025 ($0.21 Mil) but then stayed the same from Sep. 2025 ($0.21 Mil) to Dec. 2025 ($0.18 Mil).

Bioporto AS's annual Other Current Receivables increased from Dec. 2023 ($0.17 Mil) to Dec. 2024 ($0.19 Mil) but then declined from Dec. 2024 ($0.19 Mil) to Dec. 2025 ($0.18 Mil).

Bioporto AS Other Current Receivables Related Terms

Bioporto AS Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Bioporto AS's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioporto AS Other Current Receivables Chart

Bioporto AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.25 0.17 0.19 0.18

Bioporto AS Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.23 0.29 0.21 0.18
THOXF
69GF Score
Bioporto AS THOXF
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioporto AS Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $0.18 Mil mean?
Bioporto AS (THOXF) has a Other Current Receivables of $0.18 Mil as of Dec. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Bioporto AS and its competitors.
Is Bioporto AS's Other Current Receivables too high?
Bioporto AS's current Other Current Receivables is $0.18 Mil. Overall, Bioporto AS has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Bioporto AS's Other Current Receivables compare to TMO and DHR?
Bioporto AS's Other Current Receivables of $0.18 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Medical Diagnostics & Research company?
A good Other Current Receivables depends on the Medical Diagnostics & Research industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Bioporto AS and its competitors. Bioporto AS's current Other Current Receivables is $0.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioporto AS stock overvalued right now?
Bioporto AS (THOXF) has a current Other Current Receivables of $0.18 Mil. The stock's GF Value™ is $0.16, compared to a current price of $0.15 — trading 6.9% below its estimated fair value. The current Other Current Receivables is $0.18 Mil. Bioporto AS's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Bioporto AS (THOXF), the current Other Current Receivables is $0.18 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioporto AS (THOXF) Overvalued in 2026?

Based on GuruFocus' analysis, Bioporto AS stock appears to be undervalued. The current stock price of $0.15 is trading 6.9% below its estimated GF Value™ of $0.16.

Key valuation signals for THOXF:

  • Other Current Receivables: $0.18 Mil
  • GF Value™: $0.16 vs. price of $0.15 (6.9% below fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the THOXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioporto AS Business Description

Other Exchanges BIOPOR:Denmark
Address Tuborg Havnevej 15, Ground Floor, Hellerup, DNK, DK-2900
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
69GF Score

Get the complete analysis for THOXF

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price
$0.16
GF Value